GSK's NASH trial HORIZON completes; malaria and myeloma studies stay in viewNov 13Weekly roundup, 5 itemsbelantamab mafodotinGlaxoSmithKlineUpdated
FDA approves nivolumab for adjuvant Stage IIB/C melanoma treatmentNov 10Regulatory decisionBristol Myers Squibbnivolumab
FDA grants accelerated approval to belantamab mafodotin-blmf for multiple myelomaNov 6Regulatory decisionbelantamabbelantamab mafodotin
Takeda sees ixazomib combo results posted; zasocitinib Phase 2 vitiligo trial activeNov 6Weekly roundup, 4 itemsBristol Myers Squibbixazomib
Regeneron registers Phase 3 LINKER-AL1 trial of linvoseltamab for AL amyloidosisOct 30Weekly roundup, 6 itemscemiplimab-rwlcdupilumabUpdated
Janssen registers Phase 3 TRIlogy-6 trial in newly diagnosed multiple myelomaOct 30Weekly roundup, 5 itemsbosentandaratumumab
Regeneron registers Phase 1b hemodialysis study, Phase 1 Graves' disease trialOct 9Weekly roundup, 6 itemsamrecibartbortezomib
AbbVie registers Phase 3 trial of etentamig vs Dara-CyBorD in AL amyloidosisAug 28Trial updateAbbViedexamethasone
Nexcella registers Phase 3 NEXICART-3 trial of CAR-T NXC-201 in AL amyloidosisJul 16Trial updateImmix Biopharma, Inc.